KARIM YAQUB IBRAHIM

Índice h a partir de 2011
10
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/48 - Laboratório de Imunologia, Hospital das Clínicas, Faculdade de Medicina
LIM/47 - Laboratório de Hepatologia por Vírus, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor e Coautores FMUSP-HC Normalizados: ANA KAROLINA BARRETO BERSELLI MARINHO × Autor e Coautores FMUSP-HC Normalizados: ANA MARLI CHRISTOVAM SARTORI ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • conferenceObject
    Extensive local reaction after vaccination
    (2018) LARA, A. N.; IGNOTO, B.; TABORDA, M.; MARINHO, A. K. B.; MIYAJI, K.; GONCALVES, D. G.; GALASTRI, A.; IBRAHIM, K.; LOPES, M. H.; SARTORI, A. M.
  • article 0 Citação(ões) na Scopus
    Immunogenicity of COVID-19 adsorbed inactivated vaccine (CoronaVac) and additional doses of mRNA BNT162b2 vaccine in immunocompromised adults compared with immunocompetent persons
    (2024) IBRAHIM, Karim Yaqub; MOREIRA, Raquel Megale; SANTOS, Carolina Ferreira dos; STRABELLI, Tania Mara Varejao; BELIZARIO, Juliana de Cassia; PINTO, Maria Isabel de Moraes; MARINHO, Ana Karolina Barreto Berselli; PEREIRA, Juliana Marquezi; MELLO, Liliane Saraiva de; ANDO, Mauricio Cesar; SILVA, Vitor Gabriel Lopes da; SATO, Paula Keiko; LIMA, Marcos Alves de; FRANCA, Joao Italo Dias; LOCH, Ana Paula; MIYAJI, Karina Takesaki; INFANTE, Vanessa; PRECIOSO, Alexander Roberto; SARTORI, Ana Marli Christovam
    Inactivated COVID-19 vaccines data in immunocompromised individuals are scarce. This trial assessed the immunogenicity of two CoronaVac doses and additional BNT162b2 mRNA vaccine doses in immunocompromised (IC) and immunocompetent (H) individuals. Adults with solid organ transplant (SOT), hematopoietic stem cell transplant, cancer, inborn immunity errors or rheumatic diseases were included in the IC group. Immunocompetent adults were used as control group for comparison. Participants received two CoronaVac doses within a 28-day interval. IC received two additional BNT162b2 doses and H received a third BNT162b2 dose (booster). Blood samples were collected at baseline, 28 days after each dose, pre-booster and at the trial end. We used three serological tests to detect antibodies to SARS-CoV-2 nucleocapsid (N), trimeric spike (S), and receptor binding domain (RBD). Outcomes included seroconversion rates (SCR), geometric mean titers (GMT) and GMT ratio (GMTR). A total of 241 IC and 100 H adults participated in the study. After two CoronaVac doses, IC had lower SCR than H: anti-N, 33.3% vs 79%; anti-S, 33.8% vs 86%, and anti-RBD, 48.5% vs 85%, respectively. IC also showed lower GMT than H: anti-N, 2.3 vs 15.1; anti-S, 58.8 vs 213.2 BAU/mL; and anti-RBD, 22.4 vs 168.0 U/mL, respectively. After the 3 rd and 4 th BNT162b2 doses, IC had significant anti-S and anti-RBD seroconversion, but still lower than H after the 3 rd dose. After boosting, GMT increased in IC, but remained lower than in the H group. CoronaVac two-dose schedule immunogenicity was lower in IC than in H. BNT162b2 heterologous booster enhanced immune response in both groups.